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AbstrAct:
The Mdm2/p53 pathway is compromised in more than 50% of all human cancers, 
therefore it is an intensive area of research to understand the upstream regulatory 
pathways governing Mdm2/p53 activity. Mdm2 is frequently overexpressed 
in human cancers while the molecular mechanisms underlying the timely 
destruction of Mdm2 remain unclear. We recently reported that Casein Kinase I 
phosphorylates Mdm2 at multiple sites to trigger Mdm2 interaction with, and 
subsequent ubiquitination and destruction by the SCFβ-TRCP E3 ubiquitin ligase. We 
also  demonstrated  that  the  E3  ligase  activity-deficient  Mdm2  was  still  unstable 
in  the  G1  phase  and  could  be  efficiently  degraded  by  SCFβ-TRCP.  Thus  our  finding 
expands  the  current  knowledge  on  how  Mdm2  is  tightly  regulated  by  both  self- 
and SCFβ-TRCP-dependent ubiquitination to control p53 activity in response to stress. 
It further indicates that loss of β-TRCP or Casein Kinase I function contributes to 
elevated Mdm2 expression that is frequently found in various types of tumors.
INtrODUctION
Recent  scientific  advances  clearly  demonstrated 
that  tumors  arise  in  a  progressive  fashion  through 
overexpression of certain set of oncogenes, concomitantly 
with loss of function mutations in key tumor suppressor 
proteins. Among the known tumor suppressor proteins, the 
p53 tumor suppressor attracts intensive research interest 
since its activity is lost or compromised in over 50% of all 
human tumors [1]. p53 exerts its tumor suppressor function 
mainly through its role as a transcription factor to activate 
a wide spectra of downstream target genes. The activation 
of these downstream targets in turn are responsible for 
p53-dependent cell cycle arrest or apoptosis upon a variety 
of cellular stresses [2, 3]. Among the ever-growing list 
of p53 targets, key players include p21, which initiates 
both G1 and G2 cell cycle arrest by inhibition of cyclin-
dependent  kinases  [4,  5];  Gadd45  and  14-3-3,  which 
participate in G2 cell cycle arrest [6, 7]; and Bax, which 
is responsible for the pro-apoptotic activity of p53 [8]. 
Different types of DNA damage signals and variations in 
the extent of DNA-damage triggers activation of a distinct 
set of p53 downstream targets, thus initiating different 
types of stress response [9]. Because of its crucial role in 
response to DNA damage, p53 is considered the guardian 
of the genome whose activity is critical for maintaining 
the integrity of the genome [10, 11]. 
Mdm2 is the major negative regulator of the p53 
pathway
p53 activity is strictly regulated in cells to prevent 
inappropriate activation [12], which could result in either 
premature  senescence  or  elevated  apoptosis  [13,  14]. 
Among  all  the  identified  negative  regulators,  Mdm2 
plays  a  critical  role  in  promoting  p53  ubiquitination 
and  subsequent  destruction  (Figure  1A)  [15,  16].  The 
physiological significance of this layer of regulation is 
demonstrated by the fact that Mdm2 knockout mice are 
embryonic lethal due to elevated p53 expression and this 
lethality can be rescued by further inactivation of p53 
[17]. 
Earlier studies showed that the inhibitory function 
of Mdm2 towards p53 relies mainly on its interaction with 
the p53 protein, a process that is subject to many layers 
of regulation (Figure 1B). In response to stresses such as 
DNA damage, activation of the ATM/ATR/CHK kinase 
pathway results in p53 phosphorylation at the Ser15 and Oncotarget 2010; 1:  685 - 690 686 www.impactjournals.com/oncotarget
SCFβ-TRCP
Mdm2
p53
CKI
CKI
DNA Damage
p53
26S
Proteasome
SCFβ-TRCP
Mdm2
Ub
Ub
Ub
P P
P P
Degradation
Cytoplasm Nucleus
Mdm2
P P P P
P P P P
Mdm2 p53
CKI Chk2
ATM
DNA Damage
SCF β-TRCP
B
A
Ub
Ub
Ub
Figure 1
Figure 1: Multi-site phosphorylation of Mdm2 by casein Kinase I triggers Mdm2 ubiquitination and destruction by 
scFβ-TRCP in response to DNA damage. 
A. In unstressed cells, p53 expression is maintained at basal level due to its interaction with Mdm2, which serves to promote p53 ubiquitination 
and subsequent destruction. In response to DNA damage, Casein Kinase I (CKI) translocates into the nucleus and phosphorylates Mdm2 
at multiple sites. The phosphorylated Mdm2 species are recognized and ubiquitinated by SCFβ-TRCP, and subsequently degraded by the 26S 
proteasome-dependent pathway.
b. p53 phosphorylation by ATM/Chk2 and Mdm2 phosphorylation by CKI positively regulate the p53 pathway. Phosphorylation of p53 by 
ATM/Chk2 triggers the dissociation of p53 from Mdm2 and stabilizes p53. However, increased p53 activity induces Mdm2 transcription, which 
serves as a negative feedback loop to induce p53 downregulation. On the other hand, in response to the genotoxic stress, the Mdm2 oncoprotein 
is quickly degraded by the CKI/SCFβ-TRCP signaling pathway.   Oncotarget 2010; 1:  685 - 690 687 www.impactjournals.com/oncotarget
Ser20 sites, which serve to disrupt the interaction between 
Mdm2 and p53. In this setting, phosphorylated p53 can 
escape  Mdm2-mediated  proteolysis  and  accumulate  to 
sufficient levels to initiate the stress response checkpoints 
[18, 19]. Previous work indicated that Mdm2, the major 
negative  regulator  of  p53,  was  also  quickly  degraded 
in  response  to  DNA  damage  signals  [20].  Hence  the 
destruction of Mdm2 is essential to allow p53 to become 
stabilized  and  fully  activated.  However,  the  molecular 
mechanisms accounting for the rapid destruction of the 
Mdm2 protein following the DNA-damage response still 
remains unclear. 
self-ubiquitination is not required for Mdm2 
destruction
Although  it  was  previously  proposed  that  Mdm2 
undergoes self-ubiquitination when cells are treated with 
DNA damaging agents [20, 21], a recent study utilizing 
transgenic  mice  elegantly  illustrated  that  the  E3  ligase 
activity of Mdm2 may not be required for the destruction 
of the Mdm2 protein [22]. We also obtained experimental 
evidence  showing  that  the  ring-finger  mutant  Mdm2, 
which is defective in its E3 ligase activity, is still unstable 
in the early G1 phase and is quickly degraded after DNA 
damage. These results strongly suggest that the destruction 
of the Mdm2 protein, which is central in regulating the 
p53 pathway, is tightly controlled by a foreign E3 ligase. 
the scFβ-TRCP E3 ubiquitin ligase mediates Mdm2 
destruction
We recently reported a novel molecular mechanism 
by  which  CKI-mediated  phosphorylation  of  Mdm2 
at  multiple  sites  triggers  β-TRCP-mediated  Mdm2 
destruction  (Figure  1A  and  1B)  [23].  Furthermore,  we 
demonstrated  that  this  mechanism  operates  both  in 
response to DNA damage stress and in normal cell cycle 
progression,  thus  tightly  controlling  the  abundance  of 
Mdm2. As a result, Mdm2 expression is low in the early 
G1 phase, and becomes elevated when cells enter the S 
phase  [24].  When  endogenous  β-TRCP  was  depleted, 
Mdm2  abundance  was  mainly  upregulated  in  the  mid-
late G1 phase. Correspondingly, the expression levels of 
p53 and its substrates p21 and Bax were reduced [23]. 
This indicates that β-TRCP-mediated Mdm2 destruction 
mainly operates in the mid-late G1 phase and that the 
fluctuation of Mdm2 might play an important role in cell 
cycle regulation through influencing the p53/p21 pathway.
It  is  well  recognized  that  most  F-box  proteins 
including  β-TRCP,  only  interact  with  their  substrates 
once they are properly phosphorylated [25]. Therefore, 
the regulation of substrate destruction mainly occurs at 
the level of the modifying enzyme, and for the case of 
Mdm2, we found that the activity of CKI determines the 
timing for Mdm2 destruction. In support of this notion, 
blocking CKI activity with a widely-used pharmaceutical 
inhibitor [26] resulted in a marked increase in the steady-
state level of Mdm2 [23]. Previous research demonstrated 
that CKI activity is subject to many layers of regulation. 
For example, Wnt signaling has been shown to positively 
regulate CKI [27] while PKA is a repressor of CKI activity 
[28]. Additionally, autophosphorylation at the C-terminus 
by CKI attenuates its own kinase activity [29]. Our studies 
indicate that CKI activity might be relatively higher in 
the  mid-late  G1  phase,  although  the  precise  molecular 
mechanism is still unclear.
the cKI signaling pathway is also involved in 
DNA damage-induced Mdm2 destruction
In agreement with previous studies, we found that 
Mdm2  destruction  was  enhanced  in  response  to  DNA 
damaging  treatment  [20,  23].  We  also  accumulated 
experimental  evidence  supporting  the  hypothesis  that 
both CKI and β-TRCP are involved in this process. First, 
inactivation  of  β-TRCP  by  siRNA  treatment  partially 
blocked Mdm2 destruction after treatment with various 
DNA  damaging  agents.  Secondly,  inactivation  of  CKI 
by  a  widely-used  pharmaceutical  inhibitor  blocked 
DNA-damage induced Mdm2 destruction. Furthermore, 
Mdm2  mutants  whose  putative  CKI  sites  have  been 
deleted displayed elevated levels of resistance to DNA 
damage-induced  proteolysis.  Although  it  was  reported 
previously that CKI kinase activity is activated by DNA 
damaging signals [30], it is unclear how CKI is involved 
in  controlling  Mdm2  destruction  after  DNA  damage. 
Our  results  argue  that  endogenous  CKI  activity  was 
not significantly altered after DNA damaging treatment 
(data not shown). However, we found that DNA damage 
led  to  increased  nuclear  accumulation  of  CKIδ,  which 
correlates with enhanced association between Mdm2 and 
CKIδ. These data indicate that DNA damage primarily 
modulates the accessibility of CKIδ cellular localization 
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Figure 2: Inverse correlation between the extent of 
Mdm2 phosphorylation status and Mdm2 protein 
stability.  CKI-mediated multi-site phosphorylation of Mdm2 
determines Mdm2 stability in cells. Oncotarget 2010; 1:  685 - 690 688 www.impactjournals.com/oncotarget
rather than its kinase activity to influence Mdm2 stability 
(Figure 1A) [23]. 
cKI-mediated multi-site phosphorylation of 
Mdm2 promotes its destruction by scFβ-TRCP
Using  both  mass  spectrometry  analysis  and  in 
vitro kinase assays, we demonstrated that the major CKI 
phosphorylation  sites  are  located  in  the  Mdm2  acidic 
domain (p2), while other minor CKI sites are located in the 
N-terminal DSG site (p1) and the C-terminal SQ cluster 
(p3) region. In a search for major phosphorylation sites 
within those regions, we found that CKI phosphorylates 
Mdm2 at multiple sites, but we were not able to find any 
single point-mutation mutant that severely impaired CKI 
phosphorylation in comparison with the various deletion 
constructs. Interestingly, the loss of CKI phosphorylation 
in various Mdm2 mutants correlated very well with their 
reduced binding affinity, and subsequently their reduced 
destruction efficiency by β-TRCP1 [23]. This suggests that 
in contrast with other known β-TRCP substrates such as 
Emi-1 or Claspin, which contains one optimized canonical 
degron  sequence,  Mdm2  contains  many  suboptimized 
degron sequences that could be phosphorylated by CKI 
(Figure  2).  It  was  found  recently  that  many  β-TRCP 
substrates  including  Cdc25A  [31]  and  Gli3  [32-34] 
share  the  same  feature  by  containing  multiple  degron 
sequences. A similar mechanism was first described for 
SCFFbw7 to degrade its well-characterized substrate Sic1. 
Sic1 contained nine suboptimized degron sequences and 
phosphorylation of at least six of them are found to be 
required for initiating the destruction process [35]. It was 
further  proposed  that  this  multi-step  phosphorylation 
might  be  a  general  mechanism  to  set  a  threshold  for 
protein-protein interaction and thus create a strict switch-
like transition [36]. Here, our studies suggested that the 
cumulative, multisite phosphorylation of Mdm2 by CKI 
might set up a “dimmer switch” for Mdm2 destruction in 
response to DNA damage (Figure 2) [23].
Both  Mdm2  self-ubiquitination  and  β-TRCP-
mediated ubiquitination contributes to Mdm2 
destruction
Mdm2  self-ubiquitination  has  been  reported  to 
play an important role in DNA-damage triggered Mdm2 
destruction [20]. However, consistent with a recent report 
[22],  we  found  that  the  ring-finger  mutant  (C464A) 
Mdm2 could still be efficiently degraded in response to 
various  DNA  damaging  treatments.  More  importantly, 
ectopic expression of CKI and β-TRCP1 could efficiently 
destroy  both  the  C464A  mutant  Mdm2  and  the  wild-
type Mdm2, indicating the ring-finger activity of Mdm2 
is not required for this process [23]. On the other hand, 
additional deletion of the p2 or p3 region greatly impaired 
β-TRCP-induced destruction of both wild-type Mdm2 and 
the C464A-Mdm2 mutant. These findings strongly imply 
that CKI-mediated phosphorylation, rather than the ring-
finger domain of Mdm2, is critical for Mdm2 destruction 
after DNA damaging treatment. 
On  the  other  hand,  we  found  that  Mdm2  self-
ubiquitination  played  a  critical  role  in  regulating  the 
steady state level of Mdm2 in cell cycle progression. This 
is demonstrated by the observation that the C464A Mdm2 
mutant was more stable than wild-type Mdm2 during the 
cell cycle progression, especially in the mid-late G1 phase 
[23]. Interestingly, we found that depleting endogenous 
β-TRCP led to further upregulation of the C464A-Mdm2 
protein. On the other hand, the Mdm2 mutant defective 
in CKI phosphorylation was much more stable as well, 
and  its  expression  was  not  responsive  to  depletion  of 
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Figure 3: Depletion of endogenous β-TRCP results in elevated Mdm2 levels, which subsequently suppress the amplitude 
of the p53 pulse in response to DNA damage. This further suggests that disruption of the CKI/SCFβ-TRCP signaling pathway, which 
governs Mdm2 ubiquitination and degradation, might lead to misregulation of the p53 activity that contributes to cancer development. Oncotarget 2010; 1:  685 - 690 689 www.impactjournals.com/oncotarget
endogenous β-TRCP. Taken together, these data indicate 
that constitutive Mdm2 destruction during the cell cycle 
progression is tightly regulated by both self-ubiquitination 
and the β-TRCP-mediated ubiquitination pathways [23]. 
However,  as  our  data  suggested,  the  β-TRCP  pathway 
might play a more important function in triggering Mdm2 
degradation after stresses such as DNA damage.
Loss of function mutation in either cKI or 
β-TRCP might contribute to Mdm2 elevation in 
tumors
The  Mdm2  protein  has  been  characterized  as  an 
oncoprotein  whose  overexpression  enhances  cellular 
transformation. It is also widely accepted that Mdm2 is 
overexpressed in many types of tumors [37]. Although 
amplification has been found in many cases, the molecular 
mechanisms leading to elevated Mdm2 expression still 
remain unclear. Our studies suggested that dysfunction 
of  the  Mdm2  destruction  pathway  could  potentially 
contribute to Mdm2 upregulation. This could be achieved 
by either inactivation of the responsible E3 ligase β-TRCP1 
or  by  inactivation  of  the  upstream  modifying  enzyme 
CKI. Alternatively, it could also be achieved by acquiring 
Mdm2 mutations that disrupt one or several of the multi-
site phosphorylation events by CKI. Indeed, deletion of 
β-TRCP1 has been reported in many types of cancers [38, 
39]. Our data demonstrated that inactivation of β-TRCP1 
resulted  in  significant  upregulation  of  Mdm2,  and 
subsequent downregulation of p53 activity. As a result, the 
cells are more resistant to DNA-damage induced apoptosis. 
Furthermore, our studies demonstrated that after depletion 
of β-TRCP, the oscillation of p53 expression in response 
to  persistent  DNA  damage  is  affected  (Figure  3)  [23]. 
This result provided the molecular mechanism by which 
p53 activity can be dampered after depletion of β-TRCP. 
Altogether, this work suggests that a compromised Mdm2 
destruction  pathway  might  lead  to  subsequent  Mdm2 
stabilization,  thus  enhancing  Mdm2  oncogenic  activity 
by  promoting  p53  destruction  and  facilitating  tumor 
progression. Therefore, our research provides insight into 
the underlying molecular mechanisms for the frequently 
observed Mdm2 overexpression in many types of tumors. 
This opens new avenues for the development of new anti-
cancer  drugs  or  regimens  for  treating  cancer  patients, 
especially those with elevated expression of the Mdm2 
oncoprotein.
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